Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Complete title: A Phase 1, Open-Label, Dose-Escalation Study ofOlaratumab as a Single Agent and in Combination withDoxorubicin, Vincristine/Irinotecan, or High-DoseIfosfamide in Pediatric Patients with Relapsed orRefractory Solid Tumors

Research Study Number SC-6017
 
Principal Investigator Doug Hawkins, MD
 
Phase I

Research Study Description

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has two parts. In each part, a specific dose of olaratumab will be given for 21 days, followed by one of three standard chemotherapy regimens. Participants will only enroll in one part.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number SC-6017
 
Contact Alvin Russell Ongoco
 
E-mail
 

Keywords: Solid Tumors; Neoplasms; Neoplasm Metastasis

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials